M2 SURGERY
ActiveSummary
M2 SURGERY has been active since 2019 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €777,584 and a net result of €196,119. Equity is growing by ~52.9% per year across the filed fiscal years. Its solvency ranks better than 35% of 19921 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 0.2% (very low).
Checked score
Score 2024
Axes · tick = 2023
Profitability83▼-6
Solvency76▲+8
Growth78=
Track record100
Bankruptcy probability, 12 months
0.2%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €65,000 at 30 days acceptable
Liquidity ample (current ratio 3.89 against 3.74 in 2023; short-term debt: 7.8% and cash: 26% of total assets), and 49.2% of the assets are financed with debt.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 86
Relative position
BE, all sectors
reference
Human health activities (NACE 86)
about 87% fewer bankruptcies
← fewer bankruptcies
more bankruptcies →
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2024Solvency, return and age of the figures
Solvency
50.8%
Return on assets
12.8%
Age of the figures
21 mo
neutral · Filed after the deadline
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 30-09-2025, 61 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 6 filingsDeviation from the deadline
2025
not confirmed
2024
61 d late
2023
26 d late
2022
58 d late
2021
31 d late
2020
84 d late
2019
115 d late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 6 accounts on average 63 days after the deadline; the sector median for financial year 2024 is 7 days before the deadline, and 36% of the sector filed late.
Checked, nothing found (1)
History
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2024, micro schema
Equity
€777,584▲ 33.0%
2023 · €584,820
Total assets
€1.5m▲ 12.5%
2023 · €1.4m
Net result
€196,119▼ 10.3%
2023 · €218,612
Working capital
€345,647▲ 34.9%
2023 · €256,145
Trend over the years
In euros
In per cent
Ratio
In euros
No line ticked in this group.
In per cent
No line ticked in this group.
Ratio
No line ticked in this group.
Untick a line to hide it. Point at a year (or use the arrow keys on the chart) for the exact figures; the table below gives them all.Sector: the middle half (P25 to P75) of NACE 86, Human health activities, each year against the same schema; no band under 30 filings. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA).
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20202021202220232024
Operating result€186,596▲ 475%€101,822▼ 45.4%€181,289▲ 78.0%€304,201▲ 67.8%€350,059▲ 15.1%
Net result€143,177above the sector's middle half▲ 517%€70,251within the sector's middle half▼ 50.9%€127,236above the sector's middle half▲ 81.1%€218,612above the sector's middle half▲ 71.8%€196,119above the sector's middle half▼ 10.3%
Equity€170,387within the sector's middle half▲ 526%€240,638within the sector's middle half▲ 41.2%€367,874within the sector's middle half▲ 52.9%€584,820above the sector's middle half▲ 59.0%€777,584above the sector's middle half▲ 33.0%
Total assets€199,713within the sector's middle half▲ 414%€1.1mabove the sector's middle half▲ 461%€1.2mabove the sector's middle half▲ 9.6%€1.4mabove the sector's middle half▲ 10.8%€1.5mabove the sector's middle half▲ 12.5%
Debt€29,326▲ 152%€879,753▲ 2,900%€859,646▼ 2.3%€774,987▼ 9.8%€726,086▼ 6.3%
Working capital€168,648within the sector's middle half▲ 520%€146,796within the sector's middle half▼ 13.0%€116,541within the sector's middle half▼ 20.6%€256,145within the sector's middle half▲ 120%€345,647above the sector's middle half▲ 34.9%
Solvency85.3%above the sector's middle half▲ 15.3pp21.5%below the sector's middle half▼ 63.8pp30.0%below the sector's middle half▲ 8.5pp43.0%within the sector's middle half▲ 13.0pp50.8%within the sector's middle half▲ 7.8pp
Current ratio6.75above the sector's middle half▲ 3.412.63within the sector's middle half▼ 4.121.85within the sector's middle half▼ 0.793.74within the sector's middle half▲ 1.893.89within the sector's middle half▲ 0.16
Return on assets (ROA)71.7%above the sector's middle half▲ 11.9pp6.3%below the sector's middle half▼ 65.4pp10.4%within the sector's middle half▲ 4.1pp16.1%within the sector's middle half▲ 5.7pp12.8%within the sector's middle half▼ 3.3pp
above
within
below
the middle half (P25 to P75) of NACE 86, Human health activities, each year against the same schema; no band under 30 filings.
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
After the dip in 2021 the operating result has climbed three years in a row; 2024 is 15% above 2023 and is the highest result in the available series.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €1.5m
Fixed assets
€1.1m ▲ 5.5%
Current assets
€465,141 ▲ 33.0%
Equity and liabilities €1.5m
Equity
€777,584 ▲ 33.0%
Provisions
€26,600
Debt
€726,086 ▼ 6.3%
Debt's share of the balance-sheet total falls from 57.0% to 47.4%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€390,881▲
2023 · €338,108
Cash flow
€236,941▼
2023 · €252,518
Debt to equity
0.93▼
2023 · 1.33
ROE
25.2%▼
2023 · 37.4%
Interest coverage
5.80▼
2023 · 56.31
Debt ≤ 1 year
€119,494▲
2023 · €93,620
Debt > 1 year
€606,593▼
2023 · €681,367
Income taxes
€87,288▲
2023 · €79,585
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 6,781 companies that looked in July 2024 the way this one looks now, 0.6% went bankrupt within 24 months and 97% are still going.
- Small
- 5 to 10 years old
- solvency 30% or more
- a profit of 5% of the balance sheet or more
0.6%
went bankrupt
2.7%
stopped otherwise
97%
still going
For this company itself Checked computes a bankruptcy probability of 0.2% over twelve months; the group does not contradict it.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,340 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 1.0% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 6,781 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €344 | €1,157 | €18,348 | €33,907 | €40,822 | ▲ 20.4% |
| Provisions for liabilities and charges: additions (uses and reversals)635/8 | - | - | - | - | €26,600 | - |
| Other operating charges640/8 | - | €657 | €5,016 | €7,458 | €10,430 | ▲ 39.8% |
| Gross operating margin9900 | €188,138 | €103,637 | €204,653 | €345,566 | €427,911 | ▲ 23.8% |
| Operating profit (loss)9901 | €186,596 | €101,822 | €181,289 | €304,201 | €350,059 | ▲ 15.1% |
| Financial income75/76B | - | €0 | €0 | - | €772 | - |
| Recurring financial income75 | €1 | €0 | €0 | - | €772 | - |
| Financial charges65/66B | - | €2,444 | €6,480 | €6,005 | €67,423 | ▲ 1,023% |
| Recurring financial charges65 | €123 | €2,444 | €6,480 | €6,005 | €67,423 | ▲ 1,023% |
| Profit (loss) for the period before taxes9903 | €186,474 | €99,379 | €174,809 | €298,196 | €283,407 | ▼ 5.0% |
| Income taxes67/77 | €43,297 | €29,128 | €47,572 | €79,585 | €87,288 | ▲ 9.7% |
| Profit (loss) for the period9904 | €143,177 | €70,251 | €127,236 | €218,612 | €196,119 | ▼ 10.3% |
| Profit (loss) for the period to be appropriated9905 | €143,177 | €70,251 | €127,236 | €218,612 | €196,119 | ▼ 10.3% |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €199,713 | €1.1m | €1.2m | €1.4m | €1.5m | ▲ 12.5% |
| Fixed assets21/28 | €1,739 | €883,811 | €973,718 | €1.0m | €1.1m | ▲ 5.5% |
| Tangible fixed assets22/27 | €1,739 | €883,811 | €973,718 | €1.0m | €1.1m | ▲ 5.5% |
| Land and buildings22 | - | €881,638 | €869,421 | €852,990 | €842,559 | ▼ 1.2% |
| Plant, machinery and equipment23 | - | - | €93,239 | €130,771 | €204,728 | ▲ 56.6% |
| Furniture and vehicles24 | - | €2,174 | €11,058 | €26,282 | €17,842 | ▼ 32.1% |
| Current assets29/58 | €197,974 | €236,579 | €253,803 | €349,764 | €465,141 | ▲ 33.0% |
| Amounts receivable within one year40/41 | €57 | - | - | €5,915 | €60,193 | ▲ 918% |
| Trade receivables40 | - | - | - | €5,500 | €59,497 | ▲ 982% |
| Other amounts receivable41 | - | - | - | €415 | €696 | ▲ 67.6% |
| Cash at bank and in hand54/58 | €151,795 | €184,869 | €253,803 | €305,925 | €397,738 | ▲ 30.0% |
| Deferred charges and accrued income490/1 | - | €51,710 | €0 | €37,924 | €7,210 | ▼ 81.0% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €199,713 | €1.1m | €1.2m | €1.4m | €1.5m | ▲ 12.5% |
| Equity10/15 | €170,387 | €240,638 | €367,874 | €584,820 | €777,584 | ▲ 33.0% |
| Contributions10/11 | - | €4,000 | €4,000 | €4,000 | €4,000 | = |
| Outside capital11 | - | €4,000 | - | - | - | - |
| Share premium1100/10 | - | €4,000 | - | - | - | - |
| Reserves13 | €20,000 | €90,251 | €217,487 | €289,837 | €339,837 | ▲ 17.3% |
| Distributable reserves133 | - | €90,251 | €217,487 | €289,837 | €339,837 | ▲ 17.3% |
| Profit (loss) carried forward14 | €146,387 | €146,387 | €146,387 | €290,983 | €433,747 | ▲ 49.1% |
| Provisions and deferred taxes16 | - | - | - | - | €26,600 | - |
| Provisions for liabilities and charges160/5 | - | - | - | - | €26,600 | - |
| Environmental obligations163 | - | - | - | - | €26,600 | - |
| Amounts payable17/49 | €29,326 | €879,753 | €859,646 | €774,987 | €726,086 | ▼ 6.3% |
| Amounts payable after more than one year17 | - | €789,969 | €722,385 | €681,367 | €606,593 | ▼ 11.0% |
| Financial debts170/4 | - | €789,969 | €722,385 | €681,367 | €606,593 | ▼ 11.0% |
| Amounts payable within one year42/48 | €29,326 | €89,784 | €137,262 | €93,620 | €119,494 | ▲ 27.6% |
| Current portion of amounts payable after more than one year42 | - | €67,086 | €67,585 | €71,020 | €73,368 | ▲ 3.3% |
| Trade debts44 | €2,916 | €1,190 | €9,634 | €15,094 | €5,807 | ▼ 61.5% |
| Suppliers440/4 | - | €1,190 | €9,634 | €15,094 | €5,807 | ▼ 61.5% |
| Taxes, remuneration and social security45 | - | €14,418 | €36,990 | €0 | - | - |
| Taxes450/3 | - | €14,418 | €36,990 | €0 | - | - |
| Other amounts payable47/48 | - | €7,090 | €23,053 | €7,506 | €40,319 | ▲ 437% |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €143,177 | €70,251 | €127,236 | €218,612 | €196,119 | ▼ 10.3% |
| + Depreciation and write-downs630 | €344 | €1,157 | €18,348 | €33,907 | €40,822 | ▲ 20.4% |
| Operating cash flow (approximation) | €143,521 | €71,409 | €145,585 | €252,518 | €236,941 | ▼ 6.2% |
| Investment in fixed assets (approximation) | - | -€883,230 | -€108,255 | -€70,232 | -€95,909 | ▼ 36.6% |
| Change in cash | - | €33,074 | €68,934 | €52,122 | €91,813 | ▲ 76.2% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
2025
30-09
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema · 61 days late
2024
26-08
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema · 26 days late
2023
31-12
Financial
Highest result since 2019net €218,612 ▲71.8%
Net result €218,612, the highest in the series.
31-12
Financial
Liquidity doublescurrent ratio 3.74
Current ratio from 1.85 to 3.74; short-term debt falls from €137,262 to €93,620.
31-12
Financial
Equity above €500,000Eq €584,820 ▲59%
5 profitable years in a row build equity to €584,820.
27-09
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema · 58 days late
2022
31-08
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema · 31 days late
2021
31-12
Financial
Equity above €200,000Eq €240,638 ▲41.2%
3 profitable years in a row build equity to €240,638.
23-10
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema · 84 days late
2020
31-12
Financial
Liquidity doublescurrent ratio 6.75
Current ratio from 3.34 to 6.75.
31-12
Financial
Equity above €150,000Eq €170,387 ▲526%
2 profitable years in a row build equity to €170,387.
23-11
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema · 115 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 2 acts read
About the unread acts
We know of 2 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
2 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Rebecq · 1 establishment unit since 2019
Ground area
5,709 m²
Building footprint
461 m²
Volume, LiDAR
5,971 m³
2 parcels, Brussels, Wallonia · tallest building 26.1 m, ±7 floors. Linked by address, not a title deed.
2
companies at this address
See who is registered here
1 establishment unit
M2 SURGERY
since 20192.292.061.302
2 parcels
Wallonia
1
(50%)
Brussels
1
(50%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21383B0049/00R011 | Brussels | 4,506 m² | 1 · 292 m² | 26.1 m · 7 fl. |
| 25007B0313/00D000 | Wallonia | 1,203 m² | 1 · 169 m² | - |
Linked by address, not proof of ownership
Good to know
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Recognitions · licences · registrations
Legal Entity Identifier
98450007D72C66CV4540
Similar companies · same sector, comparable size
VANDERHAEGEN - VANDENBOSCH
BE 0434.164.971
Zelzate · Eq €777,416
LIENOU MEDICALE
BE 0893.170.456
Châtelet · Eq €777,946
DOKTER KRISTOF FRANCOIS
BE 0632.786.428
Langemark-Poelkapelle · Eq €778,112
DOKTER TONY DEGROOTE
BE 0438.017.752
Anzegem · Eq €779,712
Dr. Huppertz-Marx
BE 0452.533.605
Amel · Eq €774,658
Of 9,130 companies in sector 86210 we hold annual accounts for 6,337. 4,446 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPrivate limited company
Founded15-07-2019
Fiscal year end31-12
Activities, NACEBEL 2025
86210General medical practice
86220Specialist medical practice
E-invoicing
Reachable via Peppol
Peppol ID
0208:0730684370
Registered
03-12-2025
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 30 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.